Citius Oncology (CTOR) Receivables (2025 - 2026)

Citius Oncology (CTOR) recorded quarterly Receivables of $1.1 million in Q1 2026, down 73.35% quarter-over-quarter from $4.0 million in Q4 2025.

Citius Oncology (CTOR) Receivables (2025 - 2026) Analysis & Trends

Citius Oncology's Receivables history runs 2 years deep, the most recent figure standing at $1.1 million for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 3.39 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 1.51 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 312.00 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 31.29 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 768.10 Mn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 1.15 Bn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 407.63 Mn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 355.67 Mn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn 149.62 Mn
10 Citius Oncology 75.12 Mn 72.49 Mn 1.34 Mn 1.08 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.08 Mn
Dec 31, 2025 4.05 Mn